Cardiovascular Events Associated with Antipsychotics in Newly Diagnosed Parkinson’s Disease Patients: A Propensity Score Matched Cohort Study

References

• Alves M, Caldeira D, Ferro JM, Ferreira JJ. Does Parkinson’s disease increase the risk of cardiovascular events? A systematic review and meta-analysis. Eur J Neurol. 2020;27(2):288–296. doi:10.1111/ene.14076
   PubMed Web of Science ®Google Scholar
• Scorza FA, Fiorini AC, Scorza CA, Finsterer J. Cardiac abnormalities in Parkinson’s disease and Parkinsonism. J Clin Neurosci. 2018;53:1–5. doi:10.1016/j.jocn.2018.04.031
   PubMed Web of Science ®Google Scholar
• McLean G, Hindle JV, Guthrie B, Mercer SW. Co-morbidity and polypharmacy in Parkinson’s disease: insights from a large Scottish primary care database. BMC Neurol. 2017;17(1):126. doi:10.1186/s12883-017-0904-4
   PubMed Web of Science ®Google Scholar
• Yang YW, Hsieh TF, Li CI, et al. Increased risk of Parkinson disease with diabetes mellitus in a population-based study. Medicine (Baltimore). 2017;96(3):e5921. doi:10.1097/MD.0000000000005921
   PubMed Web of Science ®Google Scholar
• Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med. 2007;356(1):29–38. doi:10.1056/NEJMoa062222
   PubMed Web of Science ®Google Scholar
• Crispo JAG, Willis AW, Thibault DP, et al. Associations between cardiovascular events and nonergot dopamine agonists in parkinson’s disease movement disorders clinical practice. Movement Disorders Clin Practice. 2016;3(3):257–267. doi:10.1002/mdc3.12286
   PubMedGoogle Scholar
• Waring WS. Clinical use of antidepressant therapy and associated cardiovascular risk. Drug Healthc Patient Saf. 2012;4:93. doi:10.2147/DHPS.S28804
   PubMedGoogle Scholar
• Rotella F, Cassioli E, Calderani E, et al. Long-term metabolic and cardiovascular effects of antipsychotic drugs. A meta-analysis of randomized controlled trials. Eur Neuropsychopharmacol. 2020;32:56–65. doi:10.1016/j.euroneuro.2019.12.118
   PubMed Web of Science ®Google Scholar
• Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci. 2017. doi:10.1038/nrn.2017.62
   Web of Science ®Google Scholar
• Marras C, Kopp A, Qiu F, et al. Antipsychotic use in older adults with Parkinson’s disease. Mov Disord. 2007;22(3):319–323. doi:10.1002/mds.21192
   PubMed Web of Science ®Google Scholar
• Wang MT, Lian PW, Yeh CB, Yen CH, Ma KH, Chan AL. Incidence, prescription patterns, and determinants of antipsychotic use in patients with Parkinson’s disease. Mov Disord. 2011;26(9):1663–1669. doi:10.1002/mds.23719
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration (FDA) Public Health Advisory. Deaths with antipsychotics in elderly patients with behavioral disturbances. Department of Health and Human Services, U.S. Government; 2005. Available from: www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm053171.htm. Accessed June 2.
   Google Scholar
• Food and Drug Administration (FDA). Information for Healthcare Professionals—antipsychotics. Department of Health and Human Services, U.S. Government; 2008. Available from: www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124830.htm. Accessed June 2.
   Google Scholar
• Weintraub D, Chiang C, Kim HM, et al. Antipsychotic use and physical morbidity in parkinson disease. Am j Geriatric Psychiatry. 2017;25(7):697–705. doi:10.1016/j.jagp.2017.01.076
   PubMed Web of Science ®Google Scholar
• Weintraub D, Chiang C, Kim HM, et al. Association of antipsychotic use with mortality risk in patients with parkinson disease. JAMA Neurol. 2016;73(5):535–541. doi:10.1001/jamaneurol.2016.0031
   PubMed Web of Science ®Google Scholar
• Ballard C, Isaacson S, Mills R, et al. Impact of current antipsychotic medications on comparative mortality and adverse events in people with parkinson disease psychosis. J Am Med Dir Assoc. 2015;16(10):898e1–7. doi:10.1016/j.jamda.2015.06.021
   Web of Science ®Google Scholar
• Hirsch L, Yang J, Bresee L, Jette N, Patten S, Pringsheim T. Second-generation antipsychotics and metabolic side effects: a systematic review of population-based studies. Drug Safety. 2017;40(9):771–781. doi:10.1007/s40264-017-0543-0
   PubMed Web of Science ®Google Scholar
• Barbui C, Gastaldon C, Papola D, Ostuzzi G. Antipsychotic drug exposure and risk of myocardial infarction. Epidemiol Psychiatr Sci. 2017;26(1):18–21. doi:10.1017/S204579601600086X
   PubMed Web of Science ®Google Scholar
• Papola D, Ostuzzi G, Gastaldon C, et al. Antipsychotic use and risk of life-threatening medical events: umbrella review of observational studies. Acta Psychiatr Scand. 2019;140(3):227–243. doi:10.1111/acps.13066
   PubMed Web of Science ®Google Scholar
• Correll CU, Frederickson AM, Kane JM, Manu P. Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res. 2007;89(1–3):91–100. doi:10.1016/j.schres.2006.08.017
   PubMed Web of Science ®Google Scholar
• Lin ST, Chen CC, Tsang HY, et al. Association between antipsychotic use and risk of acute myocardial infarction: a nationwide case-crossover study. Circulation. 2014;130(3):235–243. doi:10.1161/CIRCULATIONAHA.114.008779
   PubMed Web of Science ®Google Scholar
• Malekizadeh Y, Williams G, Kelson M, et al. Whole transcriptome in silico screening implicates cardiovascular and infectious disease in the mechanism of action underlying atypical antipsychotic side effects. Alzheimers Dement (N Y). 2020;6(1):e12078. doi:10.1002/trc2.12078
   PubMedGoogle Scholar
• Beauchemin M, Geguchadze R, Guntur AR, et al. Exploring mechanisms of increased cardiovascular disease risk with antipsychotic medications: risperidone alters the cardiac proteomic signature in mice. Pharmacol Res. 2020;152:104589. doi:10.1016/j.phrs.2019.104589
   PubMed Web of Science ®Google Scholar
• May M, Beauchemin M, Vary C, Barlow D, Houseknecht KL. The antipsychotic medication, risperidone, causes global immunosuppression in healthy mice. PLoS One. 2019;14(6):e0218937. doi:10.1371/journal.pone.0218937
   PubMed Web of Science ®Google Scholar
• Nielsen R-E, Lolk A, Rodrigo-Domingo M, Valentin J-B, Andersen K. Antipsychotic treatment effects on cardiovascular, cancer, infection, and intentional self-harm as cause of death in patients with Alzheimer’s dementia. Eur Psychiatry. 2017;42:14–23. doi:10.1016/j.eurpsy.2016.11.013
   PubMed Web of Science ®Google Scholar
• Steinberg M, Lyketsos CG. Atypical antipsychotic use in patients with dementia: managing safety concerns. Am J Psychiatry. 2012;169(9):900–906. doi:10.1176/appi.ajp.2012.12030342
   PubMed Web of Science ®Google Scholar
• Jones KHFD, Lyons RA. The SAIL databank: 10 years of spearheading data privacy and research utility, 2007–2017. University S; 2017.
   Google Scholar
• Robinson D, Schulz E, Brown P, Price C. Updating the Read Codes: user-interactive maintenance of a dynamic clinical vocabulary. J Am Med Inform Assoc. 1997;4(6):465–472. doi:10.1136/jamia.1997.0040465
   PubMed Web of Science ®Google Scholar
• Parkinson’s UK. The prevalence and incidence of Parkinson’s in the UK. Parkinson’s UK; 2017. Available from: https://www.parkinsons.org.uk/sites/default/files/2018-01/Prevalence%20%20Incidence%20Report%20Latest_Public_2.pdf. Accessed January 25, 2018.
   Google Scholar
• Rochon PA, Stukel TA, Sykora K, et al. Atypical antipsychotics and parkinsonism. Arch Intern Med. 2005;165(16):1882–1888. doi:10.1001/archinte.165.16.1882
   PubMed Web of Science ®Google Scholar
• Van Den Eeden SK, Tanner CM, Bernstein AL, et al. Incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity. Am J Epidemiol. 2003;157(11):1015–1022. doi:10.1093/aje/kwg068
   PubMed Web of Science ®Google Scholar
• Schrag A, Schott JM. Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism. Lancet Neurol. 2006;5(4):355–363. doi:10.1016/S1474-4422(06)70411-2
   PubMed Web of Science ®Google Scholar
• Faustino PR, Duarte GS, Chendo I, et al. Risk of developing parkinson disease in bipolar disorder: a systematic review and meta-analysis. JAMA Neurol. 2020;77(2):192–198. doi:10.1001/jamaneurol.2019.3446
   PubMed Web of Science ®Google Scholar
• Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46(3):399–424. doi:10.1080/00273171.2011.568786
   PubMed Web of Science ®Google Scholar
• Stewart J, Manmathan G, Wilkinson P. Primary prevention of cardiovascular disease: a review of contemporary guidance and literature. JRSM Cardiovasc Dis. 2017;6:2048004016687211. doi:10.1177/2048004016687211
   Web of Science ®Google Scholar
• Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: an Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation. 2016;134(10):e123–55. doi:10.1161/CIR.0000000000000404
   PubMed Web of Science ®Google Scholar
• Nezafati MH, Vojdanparast M, Nezafati P. Antidepressants and cardiovascular adverse events: a narrative review. ARYA Atheroscler. 2015;11(5):295–304.
   PubMed Web of Science ®Google Scholar
• McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med. 2011;8(9):e1001098. doi:10.1371/journal.pmed.1001098
   PubMed Web of Science ®Google Scholar
• Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. John Wiley & Sons; 2011.
   Google Scholar
• Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol. 2007;165(6):710–718. doi:10.1093/aje/kwk052
   PubMed Web of Science ®Google Scholar
• Vrettos I, Voukelatou P, Katsoras A, Theotoka D, Kalliakmanis A. Diseases linked to polypharmacy in elderly patients. Curr Gerontol Geriatr Res. 2017;2017:4276047. doi:10.1155/2017/4276047
   PubMedGoogle Scholar
• Csoti I, Herbst H, Urban P, Woitalla D, Wullner U. Polypharmacy in Parkinson’s disease: risks and benefits with little evidence. J Neural Transm (Vienna). 2019;126(7):871–878. doi:10.1007/s00702-019-02026-8
   PubMed Web of Science ®Google Scholar
• Marras C, Austin PC, Bronskill SE, Diong C, Rochon PA. Antipsychotic drug dispensing in older adults with parkinsonism. Am j Geriatric Psychiatry. 2018;26(12):1244–1257. doi:10.1016/j.jagp.2018.08.003
   PubMed Web of Science ®Google Scholar
• Richtand NM, Welge JA, Logue AD, Keck PE Jr, Strakowski SM, McNamara RK. Dopamine and serotonin receptor binding and antipsychotic efficacy. Neuropsychopharmacology. 2007;32(8):1715–1726. doi:10.1038/sj.npp.1301305
   PubMed Web of Science ®Google Scholar
• Rogers G, Davies D, Pink J, Cooper P. Parkinson’s disease: summary of updated NICE guidance. BMJ. 2017;358:j1951. doi:10.1136/bmj.j1951
   PubMed Web of Science ®Google Scholar
• Forsaa EB, Larsen JP, Wentzel-Larsen T, Alves G. What predicts mortality in Parkinson disease?: a prospective population-based long-term study. Neurology. 2010;75(14):1270–1276. doi:10.1212/WNL.0b013e3181f61311
   PubMed Web of Science ®Google Scholar
• Jackson JW, VanderWeele TJ, Blacker D, Schneeweiss S. Mediators of first- versus second-generation antipsychotic-related mortality in older adults. Epidemiology. 2015;26(5):700–709. doi:10.1097/EDE.0000000000000321
   PubMed Web of Science ®Google Scholar
• Zhang H, Wang L, Fan Y, et al. Atypical antipsychotics for Parkinson’s disease psychosis: a systematic review and meta-analysis. Neuropsychiatr Dis Treat. 2019;15:2137–2149. doi:10.2147/NDT.S201029
   PubMed Web of Science ®Google Scholar
• Patel RS, Bhela J, Tahir M, Pisati SR, Hossain S. Pimavanserin in parkinson’s disease-induced psychosis: a literature review. Cureus. 2019;11(7):e5257. doi:10.7759/cureus.5257
   PubMed Web of Science ®Google Scholar
• Sprenger F, Poewe W. Management of motor and non-motor symptoms in Parkinson’s disease. CNS Drugs. 2013;27(4):259–272. doi:10.1007/s40263-013-0053-2
   PubMed Web of Science ®Google Scholar